Oliva M R, Erturk S M, Ichikawa T, Rocha T, Ros P R, Silverman S G, Mortele K J
Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School Boston, MA 02115, USA.
JBR-BTR. 2012 Jul-Aug;95(4):237-42. doi: 10.5334/jbr-btr.628.
When examining patients with contrast-enhanced multidetector-row CT, we determined if the stomach and small bowel were visualized and distended better with a neutral barium sulphate suspension than with positive barium sulphate suspension or water.
After obtaining approval from our institutional review board, 156 patients (women: 84; mean age: 54 yrs) with no history of gastrointestinal tract disease were randomized prospectively to receive orally either 900 ml of neutral (0.1% w/v) barium sulphate suspension (n = 53), 900 ml of positive (2.1% w/v) barium sulphate suspension (n = 53), or 900 ml of water (n = 50), prior to undergoing contrast-enhanced abdominal and pelvic multidetector-row CT. Two independent radiologists evaluated the stomach, and small bowel, for luminal distension and wall visualization, using a five point scale. Results were compared using Kruskal-Wallis and Mann-Whitney U tests.
The walls of the stomach, and small bowel were visualized better in patients who were administered neutral barium sulphate suspension than those who were administered either positive barium sulphate suspension (p < 0.01) or water (p < 0.01). In patients who received neutral barium sulphate suspension, the stomach and small bowel were distended better compared to patients administered water (p < 0.01); the stomach, duodenum, and ileum were distended better compared to patients administered positive barium sulphate suspension (p < 0.05).
When examining patients with intravenous contrast-enhanced abdominal and pelvic multidetector-row CT, orally administered neutral barium sulphate suspension allows the gastrointestinal tract to be visualized and distended better than either positive barium sulphate suspension, or water.
在对患者进行多排螺旋CT增强扫描时,我们比较了口服中性硫酸钡混悬液、阳性硫酸钡混悬液或水后,胃和小肠的显影及扩张情况。
经机构审查委员会批准,156例无胃肠道疾病史的患者(女性84例,平均年龄54岁)被前瞻性随机分为三组,分别口服900毫升中性(0.1% w/v)硫酸钡混悬液(n = 53)、900毫升阳性(2.1% w/v)硫酸钡混悬液(n = 53)或900毫升水(n = 50),随后进行腹部和盆腔多排螺旋CT增强扫描。两名独立的放射科医生使用五点量表对胃和小肠的管腔扩张及肠壁显影情况进行评估。结果采用Kruskal-Wallis检验和Mann-Whitney U检验进行比较。
口服中性硫酸钡混悬液的患者,胃和小肠壁的显影情况优于口服阳性硫酸钡混悬液(p < 0.01)或水(p < 0.01)的患者。口服中性硫酸钡混悬液的患者,胃和小肠的扩张情况优于口服水的患者(p < 0.01);胃、十二指肠和回肠的扩张情况优于口服阳性硫酸钡混悬液的患者(p < 0.05)。
在对患者进行腹部和盆腔多排螺旋CT静脉增强扫描时,口服中性硫酸钡混悬液能使胃肠道显影及扩张情况优于阳性硫酸钡混悬液或水。